Sernova Biotherapeutics Advances with IND Application Submission
LONDON, Ontario and BOSTON – Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leader in regenerative medicine, has proudly announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). This application aims to evaluate the Cell Pouch, alongside autografted thyroid cells, in patients undergoing thyroid surgery due to benign nodular disease.
Understanding Hypothyroidism and Innovative Solutions
Hypothyroidism significantly impacts the lives of millions globally. This condition arises from the inadequate production of thyroid hormones, usually leading to a requirement for lifelong hormone replacement. Sernova’s innovative Cell Pouch intends to alleviate these concerns by potentially restoring natural thyroid function. This bio-hybrid organ seeks to offer a durable and reliable solution for patients grappling with post-operative hypothyroidism, sidestepping the necessity for immune suppression therapy.
A Commitment to Transforming Healthcare
Jonathan Rigby, CEO of Sernova, emphasized the significance of this IND submission, stating, "This represents a crucial milestone in our dedication to changing the landscape of endocrine disorder treatments. We are excited about the possibility that our Cell Pouch can not only create a nurturing environment for transplanted cells but also restore thyroid function, significantly improving quality of life for those enduring lifelong hypothyroidism."
Promising Preclinical Results
Preclinical data showcases a compelling narrative, with re-implantation of thyroid tissue into the Cell Pouch demonstrating the ability to restore key thyroid hormones—thyroxine (T4) and triiodothyronine (T3)—to normal levels after thyroidectomy, without any additional hormone therapy. Imaging and histological evaluations have indicated that healthy, functional thyroid tissue persists within the Cell Pouch five months post-implant.
Looking ahead, pending FDA approval, Sernova plans to initiate a pioneering clinical trial targeting the safety and efficacy of the Cell Pouch with autologous thyroid cells for those affected by thyroid conditions.
What is the Cell Pouch?
The Cell Pouch serves as a revolutionary development in biotherapeutics. This clinical-stage project fuses human donor cells or stem cell-derived cell therapies with the Cell Pouch to devise bio-hybrid organs tailored for chronic ailments. By utilizing this approach, the goal is to not only restore but also enhance the functionality of dysfunctional organs.
A Bright Future in Regenerative Medicine
Sernova Biotherapeutics is committed to exploring new frontiers in medical treatment, particularly focusing on diseases like type 1 diabetes and thyroid disorders. Through unwavering dedication and innovative strategies surrounding the Cell Pouch, Sernova seeks to establish a transformative impact on the treatment of chronic diseases, benefitting patients worldwide.
Contact Information
For inquiries, please reach out to David Burke, VP of Investor Relations, at (917) 751-5713 or via email at David.Burke@sernova.com. More details about Sernova can be found on their official website.
Frequently Asked Questions
What is the purpose of the IND application submitted by Sernova?
The IND application aims to evaluate the Cell Pouch bio-hybrid organ combined with autologous thyroid cells for treating patients after thyroid surgery.
What is hypothyroidism?
Hypothyroidism is a condition caused by inadequate thyroid hormone production, often requiring continuous hormone replacement therapy.
How does the Cell Pouch work?
The Cell Pouch is designed to create a supportive environment for transplanted tissues, potentially restoring normal organ function.
What are the expected outcomes from the clinical trials?
Results from the trials will focus on assessing the safety, tolerability, and effectiveness of the Cell Pouch with thyroid cells in patients.
What chronic diseases is Sernova focusing on?
Sernova is initially concentrating on treatments for type 1 diabetes and thyroid disorders through novel regenerative therapies.
